Literature DB >> 15337802

Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes.

Micheala A Aldred1, Ying Huang, Sandya Liyanarachchi, Natalia S Pellegata, Oliver Gimm, Sissy Jhiang, Ramana V Davuluri, Albert de la Chapelle, Charis Eng.   

Abstract

PURPOSE: We have previously conducted independent microarray expression analyses of the two most common types of nonmedullary thyroid carcinoma, namely papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). In this study, we sought to combine our data sets to shed light on the similarities and differences between these tumor types.
MATERIALS AND METHODS: Microarray data from six PTCs, nine FTCs, and 13 normal thyroid samples were normalized to remove interlaboratory variability and then analyzed by unsupervised clustering, t test, and by comparison of absolute and change calls. Expression changes in four genes not previously implicated in thyroid carcinogenesis were verified by reverse transcriptase polymerase chain reaction on these same samples, together with eight additional FTC tumors.
RESULTS: PTCs showed two distinct groups of genes that were either over- or underexpressed compared with normal thyroid, whereas the predominant changes in FTCs were of decreased expression. Five genes could collectively distinguish the two tumor types. PTCs showed overexpression of CITED1, claudin-10 (CLDN10), and insulin-like growth factor binding protein 6 (IGFBP6) but showed no change in expression of caveolin-1 (CAV1) or -2 (CAV2); conversely, FTCs did not express CLDN10 and had decreased expression of IGFBP6 and/or CAV1 and CAV2.
CONCLUSION: PTC and FTC show distinctive microarray expression profiles, suggesting that either they have different molecular origins or they diverge distinctly from a common origin. Furthermore, if verified in a larger series of tumors, these genes could, in combination with known tumor-specific chromosome translocations, form the basis of a valuable diagnostic tool.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337802     DOI: 10.1200/JCO.2004.08.127

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  44 in total

Review 1.  How to define follicular thyroid carcinoma?

Authors:  Kurt Werner Schmid; Nadir Rashad Farid
Journal:  Virchows Arch       Date:  2006-02-28       Impact factor: 4.064

2.  Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions.

Authors:  Carrie C Lubitz; Stacy K Ugras; J Jacob Kazam; Biaxin Zhu; Theresa Scognamiglio; Yao-Tseng Chen; Thomas J Fahey
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

3.  Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.

Authors:  Gisele Oler; Cléber P Camacho; Flávio C Hojaij; Pedro Michaluart; Gregory J Riggins; Janete M Cerutti
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

4.  ZCCHC12, a potential molecular marker of papillary thyroid carcinoma: a preliminary study.

Authors:  Qiu-li Li; Fu-jin Chen; Renchun Lai; Zhu-ming Guo; Rongzhen Luo; An-kui Yang
Journal:  Med Oncol       Date:  2011-07-08       Impact factor: 3.064

Review 5.  Tight junctions in salivary epithelium.

Authors:  Olga J Baker
Journal:  J Biomed Biotechnol       Date:  2010-02-18

6.  Hedgehog-mesenchyme gene signature identifies bi-modal prognosis in luminal and basal breast cancer sub-types.

Authors:  Wandaliz Torres-García; Maribella Domenech
Journal:  Mol Biosyst       Date:  2017-11-21

7.  Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis.

Authors:  Elliott D Crouser; Daniel A Culver; Kenneth S Knox; Mark W Julian; Guohong Shao; Susamma Abraham; Sandya Liyanarachchi; Jennifer E Macre; Mark D Wewers; Mikhail A Gavrilin; Patrick Ross; Abbas Abbas; Charis Eng
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

8.  Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.

Authors:  Debora Degl'Innocenti; Chiara Alberti; Giancarlo Castellano; Angela Greco; Claudia Miranda; Marco A Pierotti; Ettore Seregni; Maria Grazia Borrello; Silvana Canevari; Antonella Tomassetti
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

9.  High expression of claudin-1 protein in papillary thyroid tumor and its regional lymph node metastasis.

Authors:  Júlia Németh; Zsuzsanna Németh; Péter Tátrai; Ilona Péter; Aron Somorácz; Attila Marcell Szász; András Kiss; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2009-07-05       Impact factor: 3.201

10.  Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers.

Authors:  Jean-Fred Fontaine; Delphine Mirebeau-Prunier; Mahatsangy Raharijaona; Brigitte Franc; Stephane Triau; Patrice Rodien; Olivier Goëau-Brissonniére; Lucie Karayan-Tapon; Marielle Mello; Rémi Houlgatte; Yves Malthiery; Frédérique Savagner
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.